Objective: To examine providers' HPV vaccine communication among adult cigarette smokers with household members aged ≤26 years.
Methods: In this cross-sectional study, we used 2017 Health Information National Trends Survey (HINTS 5, Cycle 1; N = 3191) data to derive a subsample (n = 725/3191; 22.7%) of adults with household members aged ≤26 years. Forward stepwise multivariable logistic regression analyses were performed to examine providers' HPV vaccine communication, adjusting for patients' smoking status (main independent variable); HPV awareness and knowledge; HPV vaccine awareness and beliefs; and sociodemographic characteristics that contribute to disparities in HPV vaccine coverage.
Results: Current/former smokers (35.0%) had lower HPV-related awareness/knowledge than nonsmokers (65%). Few reported providers discussed (27.4%) or recommended (24.0%) HPV vaccine. Non-Hispanic Whites who knew HPV was a sexually transmitted disease and heard of HPV vaccine were 2-6 times more likely to report provider HPV vaccine communication. Provider HPV vaccine communication differences by smoking status were not statistically significant.
Conclusion: Providers' HPV vaccine communication was higher among adults who had higher HPV-related awareness/knowledge. Although active/passive exposure to cigarette smoke increases cervical cancer risk, providers' HPV vaccine communication was not increased for current/former smokers.
Practice Implications: Current/former smokers' HPV-related awareness/knowledge and providers' HPV vaccine communication need to be increased.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695463 | PMC |
| http://dx.doi.org/10.1016/j.pec.2019.07.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring Trusted Sources of HPV Vaccine Information Among Mexican American Parents in El Paso, Texas.
Int J Environ Res Public Health
January 2025
Department of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, TX 79968, USA.
Hispanic populations are disproportionately impacted by HPV-associated cancers. An HPV vaccine is available that protects against 90% of HPV-associated cancers. Understanding the factors associated with HPV vaccine uptake, including identifying whom individuals trust to recommend the HPV vaccine, is an important step toward developing public health interventions for promoting the HPV vaccine among Hispanic people.
View Article and Find Full Text PDFPrevalence, Incidence and Predictors of Anal HPV Infection and HPV-Related Squamous Intraepithelial Lesions in a Cohort of People Living with HIV.
Diagnostics (Basel)
January 2025
Department of Medical Biotechnologies, University of Siena, Viale Mario Bracci 16, 53100 Siena, Italy.
Anal HPV infection can cause squamous intraepithelial lesions (SILs), which are precursors of anal squamous cell carcinoma (SCC). The early detection of HPV infections and improvement of effective screening programmes are, therefore, essential to prevent progression from pre-cancerous lesions to SCC, especially in people living with HIV (PLWH), who represent a population at higher risk of HPV infection and associated lesions. Among prevention strategies, HPV vaccination is relevant too, but its efficacy in persons already infected by HPV is still debated.
View Article and Find Full Text PDFRoles of human papillomavirus in cancers: oncogenic mechanisms and clinical use.
Signal Transduct Target Ther
January 2025
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Human papillomaviruses, particularly high-risk human papillomaviruses, have been universally considered to be associated with the oncogenesis and progression of various cancers. The genome of human papillomaviruses is circular, double-stranded DNA that encodes early and late proteins. Each of the proteins is of crucial significance in infecting the epithelium of host cells persistently and supporting viral genome integrating into host cells.
View Article and Find Full Text PDFPRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.
Lancet Respir Med
January 2025
Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Background: Recurrent respiratory papillomatosis (RRP) is a rare debilitating condition caused by chronic infection with human papillomavirus (HPV) type 6 or 11. Papillomas develop in the aerodigestive tract, leading to significant voice disturbance and airway obstruction. No systemic treatment currently exists.
View Article and Find Full Text PDFInvestigation of the Potency of KALA and REV Cell-Penetrating Peptides for In Vitro/In Vivo Delivery of an HPV Multiepitope DNA Construct.
J Pept Sci
March 2025
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Developing human papillomavirus (HPV) therapeutic DNA vaccines requires an effective delivery system, such as cell-penetrating peptides (CPPs). In the current study, the multiepitope DNA constructs harboring the immunogenic and conserved epitopes of the L1, L2, and E7 proteins of HPV16/18 (pcDNA-L1-L2-E7 and pEGFP-L1-L2-E7) were delivered using KALA and REV CPPs with different properties in vitro and in vivo. Herein, after confirmation of the REV/DNA and KALA/DNA complexes, their stability was investigated against DNase I and serum protease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!